Overview

OPTIMAL>60 / DR. CHOP, Improvement of Therapy of Elderly Patients With CD20+ DLBCL Using Rituximab Optimized and Liposomal Vincristine

Status:
Active, not recruiting

Trial end date:
2024-05-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to improve the outcome of elderly patients with CD20-Aggressive B-Cell Lymphoma and to reduce the toxicity of standard used Immuno-Chemotherapy by using an optimised schedule of the monoclonal antibody Rituximab, substituting conventional by Liposomal Vincristine and by a PET-guided reduction of therapy in Combination with Vitamin D Substitution.

Phase:

Phase 3

Details

Lead Sponsor:

Universität des Saarlandes
University Hospital, Saarland

Collaborators:

German High-Grade Non-Hodgkin's Lymphoma Study Group
Spectrum Pharmaceuticals, Inc

Treatments:

Rituximab
Vincristine
Vitamin D